• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents

tetano

Editor, Senior Moderator
Chem Biol Drug Des. 2011 Jul 13. doi: 10.1111/j.1747-0285.2011.01180.x. [Epub ahead of print]
Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents.
Yu M, Liu X, Liu A, Du G, Naesens L, Vanderlinden E, De Clercq E.
Source

Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, No.44 Wenhuaxi Road, Jinan 250012, P. R. China Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
Abstract

A series of novel dihydro-alkyloxy-benzyl-oxopyrimidine (DABO) derivatives were synthesized and evaluated for their activity against influenza virus in MDCK cells. Four DABO derivatives (4a1, 4a2, 4a3, and 4d1) showed potent activity against influenza virus. Among them, compound 4a3 was the most promising lead with broad activity against influenza A (antiviral EC(50) values of 9 and 18 μM for the A/H1N1 and A/H3N2 subtype, respectively) and influenza B virus (EC(50) : 33 μM). The antiviral mechanism of action of these DABO derivatives must be quite different from that of the currently approved anti-influenza virus drugs which target the viral M2 or neuraminidase proteins. The DABO derivatives represent a new avenue for further optimization and development of novel anti-influenza virus agents.

Copyright ? 2011 John Wiley & Sons A/S.

PMID:
21752202
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21752202
 
Back
Top Bottom